VYNE Therapeutics Inc. (VYNE)
Jul 27, 2026 - VYNE was delisted (reason: merged with YARW)
28.56
+3.11 (12.22%)
Inactive · Last trade price on Jul 27, 2026
VYNE Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.45 | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 |
| 0.45 | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 | |
Revenue Growth | -24.96% | 13.77% | 18.16% | -11.11% | -48.77% | -95.56% |
Gross Profit | 0.45 | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 |
Selling, General & Admin | 10.89 | 11.08 | 13.19 | 13.38 | 16.39 | 20.3 |
Research & Development | 13.93 | 19.24 | 30.95 | 16.31 | 18.39 | 19.54 |
Operating Expenses | 24.82 | 30.32 | 44.14 | 29.68 | 34.77 | 39.84 |
Operating Income | -24.37 | -29.75 | -43.64 | -29.26 | -34.3 | -38.91 |
Interest Expense | - | - | - | - | - | -5.61 |
Interest & Investment Income | 1.35 | 1.72 | 3.83 | 1.39 | 0.36 | - |
Other Non Operating Income (Expenses) | - | - | - | - | - | -0.14 |
EBT Excluding Unusual Items | -23.01 | -28.03 | -39.8 | -27.87 | -33.93 | -44.66 |
Other Unusual Items | 1.3 | 1.3 | - | - | - | - |
Pretax Income | -21.71 | -26.73 | -39.8 | -27.87 | -33.93 | -44.66 |
Income Tax Expense | 0 | 0 | 0 | - | 0.01 | -0.45 |
Earnings From Continuing Operations | -21.72 | -26.74 | -39.81 | -27.87 | -33.95 | -44.21 |
Earnings From Discontinued Operations | 0.26 | 0.25 | -0.03 | -0.58 | 10.74 | -29.12 |
Net Income | -21.46 | -26.48 | -39.83 | -28.45 | -23.21 | -73.33 |
Preferred Dividends & Other Adjustments | - | - | - | 0.15 | - | - |
Net Income to Common | -21.46 | -26.48 | -39.83 | -28.6 | -23.21 | -73.33 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1 | 1 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 0 | 0 | 0 |
Shares Change | 0.42% | 0.42% | 314.57% | 222.44% | 11.44% | 58.75% |
EPS (Basic) | -25.07 | -30.96 | -46.77 | -139.20 | -364.25 | -1282.42 |
EPS (Diluted) | -25.07 | -30.96 | -46.77 | -139.20 | -364.25 | -1282.42 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -25.74 | -33.12 | -34.09 | -25.34 | -29.2 | -56.37 |
Free Cash Flow Per Share | -30.08 | -38.73 | -40.02 | -123.34 | -458.25 | -985.78 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -5367.40% | -5219.12% | -8709.98% | -6900.47% | -7189.73% | -4179.48% |
Profit Margin | -4726.21% | -4646.14% | -7950.90% | -6745.52% | -4865.83% | -7876.37% |
Free Cash Flow Margin | -5670.48% | -5811.23% | -6804.19% | -5976.65% | -6121.59% | -6054.46% |
EBITDA | -24.35 | -29.73 | -43.63 | -29.19 | -34.22 | -38.8 |
D&A For EBITDA | 0.02 | 0.02 | 0 | 0.07 | 0.07 | 0.11 |
EBIT | -24.37 | -29.75 | -43.64 | -29.26 | -34.3 | -38.91 |
Revenue as Reported | 0.45 | 0.57 | 0.5 | 0.42 | 0.48 | 0.93 |